Overview

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see how participants with late stage lung cancer do on gemcitabine-cisplatin chemotherapy plus necitumumab. The study will also see how safe the drugs are in combination and to see how long the medicine stays in the body. The study will last approximately 2 years.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Antibodies, Monoclonal
Cisplatin
Gemcitabine
Necitumumab